Abstract: MCC950 (also known as CRID3) is a highly potent, selective small-molecule inhibitor of the NLRP3 inflammasome, which plays a central role in the pathogenesis of numerous metabolic and autoimmune diseases. By directly targeting the NACHT domain of the NLRP3 protein and blocking ATP hydrolysis, MCC950 traps the inflammasome in an inactive conformation, thereby preventing the oligomerization of ASC and the subsequent release of pro-inflammatory cytokines IL-1β and IL-18. Extensive preclinical studies have demonstrated its robust pharmacological efficacy across a wide spectrum of conditions, including multiple sclerosis, Parkinson's disease, heart failure, and idiopathic inflammatory myopathies. Despite its promising therapeutic potential, the clinical development of MCC950 was halted during Phase II trials for rheumatoid arthritis due to dose-dependent hepatotoxicity, likely associated with its furan ring structure. Nevertheless, MCC950 remains a critical benchmark compound, providing invaluable structural and mechanistic insights that continue to guide the development of next-generation, safer NLRP3-targeted therapies.
1. Introduction
The innate immune system relies on pattern-recognition receptors (PRRs) to detect endogenous and exogenous danger signals. Among these, the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome is the most extensively characterized intracellular multiprotein complex [1][5]. Aberrant activation of the NLRP3 inflammasome is a primary driver of chronic sterile inflammation and is heavily implicated in the onset and progression of various metabolic and autoimmune diseases, including atherosclerosis, type II diabetes, gout, multiple sclerosis, and cryopyrin-associated periodic syndromes (CAPS) [1][5]. Given its central role in inflammatory pathogenesis, the NLRP3 inflammasome has emerged as a highly desirable therapeutic target. MCC950, a diarylsulfonylurea-containing compound (formerly known as CRID3), was identified as a groundbreaking, highly specific small-molecule inhibitor of the NLRP3 inflammasome [1][7]. It has since become one of the most widely utilized pharmacological tools in preclinical models to explore the therapeutic viability of NLRP3 inhibition [8].
2. Pharmacological Activity
MCC950 has demonstrated profound anti-inflammatory efficacy across over 100 preclinical models of metabolic, autoimmune, and inflammatory diseases [8]. Its pharmacological activity is characterized by the reduction of systemic and local inflammation without inducing generalized immunosuppression.
Autoimmune and Neuroinflammatory Diseases: In animal models of multiple sclerosis, such as experimental autoimmune encephalomyelitis (EAE), MCC950 significantly alleviates disease severity by reducing demyelination and immune cell infiltration [1][5]. It also reduces the severity of CAPS in mouse models [1]. In neurodegenerative contexts, oral administration of MCC950 has been shown to rescue dopaminergic neurodegeneration in mouse models of Parkinson's disease by mitigating chronic neuroinflammation [4][5].
Cardiovascular and Metabolic Diseases: Chronic NLRP3 activation drives fibrotic remodeling and plaque destabilization in cardiovascular disorders [2]. MCC950 treatment reverses hypertension in salt-sensitive mouse models [1] and attenuates adverse cardiac remodeling, hypertrophy, and fibrosis following heart failure in obese mice by improving cardiometabolic dysfunction [2]. Furthermore, it reduces arrhythmias and mitigates myocardial injury in models of viral myocarditis and ischemia-reperfusion [10]. In metabolic contexts, MCC950 enhances liver regeneration in hepatic steatosis by restoring the efferocytic capacity of macrophages and promoting a reparative phenotype [4][11].
Idiopathic Inflammatory Myopathies and Other Conditions: In polymyositis (PM) rat models, MCC950 reduces the expression of NLRP3, IL-1β, and MHC-I in muscle tissues, effectively alleviating muscle inflammation and lowering serum levels of creatine kinase (CK) and lactate dehydrogenase (LDH) [3]. Additionally, it has shown protective effects against systemic inflammation-induced sensorineural hearing loss by preventing macrophage infiltration and cochlear inflammasome activation [9].
3. Molecular Mechanism of Action
MCC950 is a direct and highly selective inhibitor of the NLRP3 inflammasome. It effectively blocks both canonical and non-canonical pathways of NLRP3 activation but does not interfere with the activation of other inflammasomes, such as NLRP1, AIM2, or NLRC4 [1][4][5].
Mechanistically, MCC950 binds directly to the NACHT domain of the wild-type NLRP3 protein [2][5]. Specifically, it targets the ATP-hydrolysis motif (the Walker B motif) within this domain, thereby blocking ATPase activity [4][5][6]. By inhibiting ATP hydrolysis, MCC950 traps the NLRP3 protein in a "closed" or inactive structural conformation [6][7]. This conformational lock prevents NLRP3 from engaging with NEK7 [12] and halts the subsequent oligomerization of the adaptor protein ASC (apoptosis-associated speck-like protein) [1][4]. Consequently, the assembly of the inflammasome complex is aborted, preventing the recruitment and activation of procaspase-1. Without active caspase-1, the proteolytic maturation and secretion of the highly inflammatory cytokines IL-1β and IL-18 are completely suppressed, and pyroptotic cell death is averted [1][4][13].
4. Structure-Activity Relationship (SAR)
MCC950 belongs to a class of diarylsulfonylurea compounds [1][5]. Structural and biochemical studies have highlighted several key functional groups that dictate its interaction with the NLRP3 protein. The sulfonylurea group is a critical pharmacophore that facilitates hydrogen bonding with specific amino acid residues within the active site of the NLRP3 NACHT domain [7]. Additionally, MCC950 features a tricyclic ring system that shapes its steric profile, allowing it to fit precisely into the binding pocket and stabilize the inhibitor-target complex [7].
A defining structural feature of MCC950 is its furan ring. While this group contributes to the molecule's potent inhibitory activity, it has also been identified as a major structural liability. The furan moiety is strongly associated with off-target carbonic anhydrase inhibition and is considered the primary structural cause of the drug-induced liver injury observed during clinical testing [7][8].
5. Current Limitations
Despite its exceptional preclinical efficacy, the clinical translation of MCC950 has been severely hindered by safety concerns. MCC950 advanced to Phase II clinical trials for the treatment of rheumatoid arthritis; however, the development program was terminated due to significant hepatotoxicity [6][7]. Patients receiving high-dose administration (approximately 1200 mg daily) exhibited alarming signals of liver toxicity, including elevated transaminase levels [6]. Furthermore, at higher concentrations, MCC950 loses its strict selectivity and exhibits off-target effects, raising concerns about its physiological specificity [4].
Another limitation is related to its efficacy against genetic variants of NLRP3. While MCC950 potently targets the NACHT domain of wild-type NLRP3, studies utilizing photoaffinity labeling have shown that its binding affinity is significantly diminished in several disease-associated NLRP3 mutants. Consequently, MCC950 failed to inhibit NLRP3-driven inflammatory pathology in certain mouse models of CAPS driven by these specific gain-of-function mutations [5].
6. Future Perspectives
The clinical failure of MCC950 provided critical lessons regarding therapeutic windows, dose selection, and hepatic safety monitoring, which have profoundly shaped the subsequent development of NLRP3 inhibitors [6]. MCC950 continues to serve as an invaluable structural template for structure-based drug design. Current medicinal chemistry efforts are heavily focused on scaffold hopping and structural optimization—specifically, replacing the problematic furan ring with aryl, heteroaryl, or amine substituents to eliminate hepatotoxicity while preserving or enhancing binding affinity to the NACHT domain [7][8].
The mechanistic insights gained from MCC950's interaction with the Walker B motif have paved the way for next-generation inhibitors (such as OLT1177/dapansutrile and GDC-2394) that aim to achieve the same conformational locking of NLRP3 but with vastly improved safety profiles [4][6][7]. As research progresses, the refined derivatives of MCC950 hold immense promise for delivering targeted, safe, and effective therapies for the growing burden of NLRP3-driven metabolic and autoimmune diseases.
